{'fraction_non_alphanumeric': 0.03608247422680412, 'fraction_numerical': 0.01718213058419244, 'mean_word_length': 5.239285714285714, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract 6131: Harnessing resveratrol-mediated restoration of MHC-I in melanoma to enhance immunotherapy


 The introduction of immunotherapy has drastically improved outcomes in cancer therapy, particularly in melanoma, the deadliest form of skin cancer. However, around half of melanoma tumors are initially resistant to treatment and a significant proportion of initial responders gain resistance later. This is in part because tumors are able to decrease their ability to be recognized by T-cells, an essential actor in immunotherapeutic action. There are two major types of T-cells: CD4+ helper and CD8+ cytotoxic. The most common method used by tumor cells to evade immune attack is to down-regulate major histocompatibility complex (MHC) class I molecules, which allow CD8+ T-cells to recognize cells to be eliminated. Thus, to increase immunotherapeutic efficacy, it is critical to identify how to safely restore MHC-I expression on cancer cells so that tumor antigens are presented to T-cells. I focused on finding potential adjuvants to immunotherapy for this purpose, and I found that resveratrol, a natural compound found in plants and associated with various medicinal properties, consistently elevated MHC-I expression in melanoma cells. Through a proteomics study, I identified that resveratrol also significantly affected pathways known to enhance MHC-I expression.
 Citation Format: Lauren C. Morehead, Brian S. Koss, Isabelle R. Miousse, Alan J. Tackett. Harnessing resveratrol-mediated restoration of MHC-I in melanoma to enhance immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6131.